CClinicalTrials.gg
Status unknownNCT03274349Updated Oct 16, 2018

Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma

An interventional study of whole body electromyostimulation exercise and protein-rich nutrition therapy in Cancer of Esophagus and Cancer, Lung, sponsored by University of Erlangen-Nürnberg Medical School. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-16.

Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective or the trial is to study the influence of a combined therapy involving protein-rich individualized nutritional therapy and highly effective muscle training via personalized whole-body electromyostimulation exercise on muscle mass, muscle functionality, physical capability, fatigue and quality of life in patients with esophageal and bronchial carcinoma in advanced or metastatic stage.

Read the detailed description

Tumor specific and inflammation promoting mediators lead to a loss of appetite, to systemic inflammation processes and to metabolic and hormonal changes including anabolic resistance. Consequences hereof are a decreased food uptake, a deteriorated nutrient utilization and a loss of muscles and/or fat leading to cancer cachexia. In addition, an accelerated muscle wasting can be a side effect of the oncologic therapy promoting cancer cachexia even further. The advancing muscle loss induces diminishing physical capability, a decreased tolerance of oncological therapy, functional losses even reaching loss of independence and a worsened prognosis.

The purpose of this study is to establish an innovative combined therapy involving protein-rich nutritional therapy and highly effective muscle training by personalized whole-body electromyostimulation (WB-EMS) exercise to improve muscle mass, functionality and strength of esophageal and bronchial carcinoma patients in advanced stage. An increase in muscle mass and strength leads to an increase in physical activity, physical capability as well as tolerance to and applicability of tumor therapy. In the course of a 3-months intervention study the efficacy of a combined protein-rich nutritional therapy with an innovative exercise therapy will be documented for patients with esophageal and bronchial carcinoma in advanced or metastatic stage. An effective stopping of the progress of muscle wasting or even increase of muscle mass, strength and function in the patients of the trial would benefit each patient and his family individually, since it could mean a considerable improvement in his quality of life and tolerability of oncological treatment.

02

Conditions studied

  • Cancer of Esophagus
  • Cancer, Lung
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with esophageal and/or bronchial carcinoma in curative or palliative treatment

Exclusion criteria

Exclusion Criteria:

  • Healthy persons or patients under age
  • Pregnancy, Lactation
  • Psychological disorders, epilepsia, sever neurological disorders
  • Participation in other exercise- or nutrition studies within the last 6 months
  • Acute cardiovascular disease
  • Rheuma
  • Intake of anabolic drugs,
  • Skin injuries in the area of electrode placements
  • Electronic implants (defibrillator, pacemaker)
  • Persons in mental hospitals by order of authorities or jurisdiction
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Control

    Group of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient

    Procedure: protein-rich nutrition therapy

  • Experimental
    EMS-group

    Group of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient

    Procedure: whole body electromyostimulation exercise · Procedure: protein-rich nutrition therapy

Interventions

  • Procedurewhole body electromyostimulation exercise

    whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec

  • Procedureprotein-rich nutrition therapy

    protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day

05

What researchers measure

Primary outcomes

  1. Muscle mass maintenance or increase, as assessed by Bioelectrical Impedance Analysis

    Maintenance or increase of skeletal muscle mass in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS, by assessing Bioelectrical Impedance Analysis values.

    Time frame: 12 weeks per patient

Secondary outcomes

  1. Increase in quality of life score by assessing the score points using EORTC-QLQ-C30 questionnaires

    Clinical improvement by an increase in quality of life in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

    Time frame: 12 weeks per patient

  2. Increase or maintenance of muscle strength, as assessed by hand grip strength measurements (Jamar dynamometry)

    Clinical improvement by an increase in muscle strength in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

    Time frame: 12 weeks per patient

  3. Improvement of pain scores, as assessed by Visual Analog Score

    Clinical improvement by an increase of pain scores in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

    Time frame: 12 weeks per patient

  4. Improvement of fatigue scores, as assessed by FACIT-Fatigue Score

    Clinical improvement by an increase of fatigue scores in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

    Time frame: 12 weeks per patient

  5. Improvement of oncological therapy tolerance, as assessed by Common Toxicity Criteria regarding gastrointestinal complaints

    Clinical improvement oncology therapy tolerance in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

    Time frame: 12 weeks per patient

  6. Maintenance or increase in Body Mass Index (BMI) in kg/m^2-analysis (combination of weight in kilograms and height and in meters

    Maintenance or increase of skeletal muscle mass in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS, by assessing BMI in kg/m\^2 (combination of weight in kilograms and height in meters).

    Time frame: 12 weeks per patient

06

Study locations

1 of 1 sites recruiting
  • University Hospital Erlangen, Department of Medicine 1
    Erlangen, Bavaria 91054, Germany
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03274349
Lead sponsor
University of Erlangen-Nürnberg Medical School
Responsible party
Sponsor
First posted
Sep 6, 2017
Start date
Mar 17, 2017
Primary completion
Mar 2021 (estimated)
Completion
Mar 2021 (estimated)
Last update
Oct 16, 2018

Study contacts

Yurdaguel Zopf, Prof.
Contact
yurdaguel.zopf@uk-erlangen.de
*49 9131 85-35000
Yurdaguel Zopf, Prof.
principal investigator · University Erlangen Nuremberg Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion